| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| GD8-H5243 | Human | Human latent GDF-8 Protein, His Tag (MALS verified) |  |
|
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Domagrozumab | PF-6252616; PF-06252616 | Phase 2 Clinical | Pfizer Inc | Muscular Dystrophy, Duchenne | Details |
| AAV1-FS344 | AAV1-FS344; AAV1-Follistatin | Phase 2 Clinical | Nationwide Children'S Hospital | Myositis, Inclusion Body; Muscular Dystrophy, Duchenne | Details |
| Trevogrumab | REGN-1033; SAR-391786 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Muscular Atrophy; Sarcopenia | Details |
| Talditercept alfa (Bristol-Myers Squibb) | RO-7239361; BMS-986089; RG-6206 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Dystrophy, Duchenne | Details |
| RG-6237 | GYM-329; RG-70240; RG-6237 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Neuromuscular Diseases | Details |
| Apitegromab | SRK-015 | Phase 3 Clinical | Scholar Rock | Spinal Muscular Atrophies of Childhood; Neuromuscular Manifestations; Muscular Atrophy; Neuromuscular Diseases; Muscular Atrophy, Spinal; Atrophy | Details |
This web search service is supported by Google Inc.
A-Z
